Systemic Therapy for Hereditary Breast Cancers.
Loading...
Embargo End Date
ICR Authors
Authors
Harvey-Jones, EJ
Lord, CJ
Tutt, ANJ
Lord, CJ
Tutt, ANJ
Document Type
Journal Article
Date
2023-02-01
Date Accepted
Abstract
Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment for such breast cancers, including approved chemotherapeutic approaches and also targeted treatment approaches using poly-(ADP ribose) polymerase inhibitors. We also discuss experimental approaches to treating hereditary breast cancer, including new small molecule DNA repair inhibitors and also immunomodulatory agents. Finally, we discuss how drug resistance emerges in patients with hereditary breast cancer, how this might be delayed or prevented, and how biomarker-adapted treatment is molding the future management of hereditary breast cancer.
Citation
Hematology / Oncology Clinics of North America, 2023, 37 (1), pp. 203 - 224
Source Title
Hematology / Oncology Clinics of North America
Publisher
W B SAUNDERS CO-ELSEVIER INC
ISSN
0889-8588
eISSN
1558-1977
1558-1977
1558-1977
Collections
Research Team
Directorate Breast Canc